 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Sep 13, 2024 |
| Title |
A potent and selective small-molecule degrader of ENL suppresses leukemia progression in vivo (RNA-Seq) |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
ENL, a stoichiometric component of the Super Elongation Complex (SEC) as well as the histone H3K79 methyltransferase DOT1L complex, is involved in the regulation of transcription elongation. Loss-of-function studies of ENL highlighted an essential role for its chromatin reader YEATS domain in the progression of acute leukemia, suggesting ENL as an attractive therapeutic target for leukemia therapy. Proteolysis targeting chimeras (PROTACs), a class of new therapeutic modalities, have the potential to degrade target proteinsthrough the ubiquitin-proteasome system. PROTACs have the potential to deliver robust therapeutic effects at low doses and infrequent dosing regimens with less side-effects. Here, we designed and synthesized a serial of ENL PROTACs. Through screening by ENL degradation in human leukemia cells, we identified MS47 as a potent ENL PROTAC. MS47 efficiently and specifically degrades ENL in a concentration-dependent and time dependent manner. In line with the mechanism of action of PROTACs, proteasome inhibitors can block ENL degradation mediated by MS47. MS47 suppresses survival and growth of a panel of acute leukemia cells, and efficiently suppresses the expression of ENL target genes, including Hoxa9, Meis1, Myb and Myc. In disseminated xenograft model, MS47 significantly benefits mouse survival, inhibits leukemia cell growth in vivo. No obvious toxic effect shown in toxicity test in vivo. Modest changes occurred on normal hematopoiesis. Together, our study developed a potent ENL PROTAC for leukemia treatment.
|
| |
|
| Overall design |
Design and synthesis ENL degraders, screen these ENL degraders via western blot to get the candidates. Then test cell growth inhibition activity of ENL degrader candidates to get the best ENL degrader. Further profile transcriptional and chromatin occupancy changes upon ENL degrader treatment to investigate the mechanism of ENL. At last, test ENL degrader efficacy in xenograft mouse model.
|
| |
|
| Contributor(s) |
Xue Z, Xuan H, Wen H |
| Citation(s) |
39196923 |
| |
| Submission date |
Oct 20, 2023 |
| Last update date |
Sep 13, 2024 |
| Contact name |
Xiaobing Shi |
| E-mail(s) |
xiaobing.shi@vai.org
|
| Organization name |
Van Andel Institute
|
| Street address |
333 Bostwick Ave. NE
|
| City |
Grand Rapids |
| ZIP/Postal code |
49503 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (42)
|
|
| This SubSeries is part of SuperSeries: |
| GSE245927 |
A potent and selective small-molecule degrader of ENL suppresses leukemia progression in vivo |
|
| Relations |
| BioProject |
PRJNA1030400 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE245926_MV411_KO_htseq_count.txt.gz |
440.9 Kb |
(ftp)(http) |
TXT |
| GSE245926_MV411_htseq_count.txt.gz |
1.3 Mb |
(ftp)(http) |
TXT |
| GSE245926_SEMK2_htseq_count.txt.gz |
500.0 Kb |
(ftp)(http) |
TXT |
| GSE245926_invivo_htseq_count.txt.gz |
485.4 Kb |
(ftp)(http) |
TXT |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data are available on Series record |
|
|
|
|
 |
Less...
More...